|
Tuesday, March 25
7:00am Registration (Open until 5:30pm)
8:00 Plenary Keynote Introduction
 Harry Glorikian, Managing Partner, Scientia Advisors
8:15 Diagnosing the Disease: Disruptive Innovation in Healthcare
 Clayton M. Christensen, DBA, Robert and Jane Cizik Professor of Business Administration, Harvard Business School
In the absence of the ability to precisely define a disease, the care of patients is best undertaken by highly skilled professionals, whose intuition is based on deep experience. This describes the history of health care, and we call this the practice of intuitive medicine. Molecular biology holds the promise of transforming medical practice into a new phase that we call precision medicine. It promises to dramatically reduce cost and increase the predictable effectiveness of therapy.
9:45 Coffee Break
10:15am 丒1:15pm Morning Pre-Conference Short Courses*
|
|
|
(SC1) Biomarkers are Us: Interactive Short Course on How Biomarkers Will
Impact the Field of Oncology
Moderator: Jorge A. Le鏮, Ph.D., President, Leomics Consulting
Experts in oncology will be invited to speak and address the following issues:
-
What is a biomarker and what does it have to comply with?
-
Where do they come from?
-
What is a good biomarker?
-
How do you validate and implement a biomarker?
-
Case studies in breast, lung, ovarian, bladder cancer
(SC2) The Challenge of the Blood-Brain Barrier 丒A Medicinal Chemisrty Perspective
Douglas K. Spracklin, Ph.D., Senior Principal Scientist, CNS Drug Metabolism, Pfizer Inc.
Ellen Q. Wang, Ph.D., Senior Principal Scientist, Pharmacokinetics, Dynamics and Metabolism, Pfizer Global
Research and Development
In this course you will learn丒/p>
-
An introduction to the physiology of the blood-brain barrier
-
In vitro methods for predicting BBB permeability
-
In vivo methods for measuring brain exposure and/or target occupancy
-
Case studies & applications
*Separate Registration Required
|
1:15 Lunch on Your Own
2:30 - 5:30 Afternoon Pre-Conference Short Courses*
|
|
|
(SC8) Models for Evaluating Drug-Drug Interaction Potential in PreClinical Development
Joseph Ware, Ph.D., Senior. Scientist, Late Stage PK/PD, Genentech, Inc.
James McKim, Ph.D., DABT, President & Chief Scientific Officer, CeeTox, Inc.
Philip S. Burton, Ph.D., Chief Executive & Scientific Officer, ADMETRx, Inc.
This course will cover:
-
An overview of drug-drug interactions from the clinical perspective, withdrawn drugs and the overall impact on development
-
CYP inhibition and induction methods and in vitro/ in vivo correlations
-
Transporter models and in vitro/in vivo correlations
*Separate Registration Required
|
|
Japanese
Korean
English